References
- van Besien K, Liu H, Jain N, et al. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013;19:682–691.
- Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118:6438–6445.
- van Besien K, Childs R. Haploidentical cord transplantation, the best of both worlds. Semin Hematol. 2016;53:257–266.
- Bachier Rodriguez L, Shore TB, Gergis U, et al. Novel risk factors for Epstein-Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorder (PTLD) after allogeneic hematopoietic stem cell transplant. Blood. 2017;130:1949.
- Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009;114:4002–4008.
- Burns DM, Rana S, Martin E, et al. Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transplant. 2016;51:825–832.
- Savani BN, Pohlmann PR, Jagasia M, et al. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?. Blood. 2009;113:6263–6264.
- Choe HK, Gergis U, Mayer SA, et al. The addition of low-dose total body irradiation to fludarabine and melphalan conditioning in haplocord transplantation for high-risk hematological malignancies. Transplantation. 2017;101:e34–ee8.
- Kline J, Pollyea DA, Stock W, et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006;37:307–310.
- Abeynayake J, Johnson R, Libiran P, et al. Commutability of the Epstein-Barr virus WHO international standard across two quantitative PCR methods. J Clin Microbiol. 2014;52:3802–3804.
- Klein JP, Rizzo JD, Zhang MJ, et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant. 2001;28:909–915.
- Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992–5001.
- Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004;33:921–923.
- Ha VH, Ghosh S, Leyshon C, et al. Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation. J Oncol Pharm Pract. 2018;24:323–331.
- Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–3671.